PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.32 Million EUR | -107.54% |
| 2022 | 3.73 Million EUR | 412.36% |
| 2021 | -1.19 Million EUR | 5.97% |
| 2020 | -1.27 Million EUR | -219.31% |
| 2019 | 1.06 Million EUR | -70.77% |
| 2018 | 3.65 Million EUR | 28.79% |
| 2017 | 2.83 Million EUR | -23.63% |
| 2016 | 3.71 Million EUR | 40.51% |
| 2015 | 2.64 Million EUR | 47.13% |
| 2014 | 1.79 Million EUR | 38.35% |
| 2013 | 1.29 Million EUR | -75.48% |
| 2012 | 5.29 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 546.5 Thousand EUR | 43.06% |
| 2024 Q2 | 176.5 Thousand EUR | 0.0% |
| 2023 Q2 | -122 Thousand EUR | -187.77% |
| 2023 FY | -282 Thousand EUR | -107.54% |
| 2023 Q3 | 197 Thousand EUR | 261.48% |
| 2023 Q4 | 382 Thousand EUR | 93.91% |
| 2023 Q1 | 139 Thousand EUR | -96.09% |
| 2022 Q3 | 470 Thousand EUR | 112.13% |
| 2022 FY | 3.73 Million EUR | 412.36% |
| 2022 Q4 | 3.55 Million EUR | 656.81% |
| 2022 Q2 | -3.87 Million EUR | -819.11% |
| 2022 Q1 | 539 Thousand EUR | 125.58% |
| 2021 Q3 | 1.13 Million EUR | 168.07% |
| 2021 FY | -1.19 Million EUR | 5.97% |
| 2021 Q4 | -2.1 Million EUR | -286.13% |
| 2021 Q1 | 1.44 Million EUR | 187.06% |
| 2021 Q2 | -1.66 Million EUR | -215.49% |
| 2020 Q4 | -1.65 Million EUR | -258.89% |
| 2020 FY | -1.27 Million EUR | -219.31% |
| 2020 Q1 | 747 Thousand EUR | 143.46% |
| 2020 Q2 | -1.33 Million EUR | -278.85% |
| 2020 Q3 | 1.04 Million EUR | 177.92% |
| 2019 Q1 | 757 Thousand EUR | -57.5% |
| 2019 Q2 | 1.11 Million EUR | 47.03% |
| 2019 FY | 1.06 Million EUR | -70.77% |
| 2019 Q4 | -1.71 Million EUR | -287.66% |
| 2019 Q3 | 916 Thousand EUR | -17.7% |
| 2018 Q4 | 1.78 Million EUR | 344.14% |
| 2018 Q3 | 401 Thousand EUR | -62.21% |
| 2018 Q2 | 1.06 Million EUR | -11.88% |
| 2018 Q1 | 1.2 Million EUR | 140.8% |
| 2018 FY | 3.65 Million EUR | 28.79% |
| 2017 Q4 | 500 Thousand EUR | -53.53% |
| 2017 Q1 | 1.22 Million EUR | 40.86% |
| 2017 Q2 | 566 Thousand EUR | -53.68% |
| 2017 FY | 2.83 Million EUR | -23.63% |
| 2017 Q3 | 1.07 Million EUR | 90.11% |
| 2016 Q2 | 1.71 Million EUR | 151.32% |
| 2016 Q4 | 867.5 Thousand EUR | 0.0% |
| 2016 Q3 | 867.5 Thousand EUR | -49.53% |
| 2016 FY | 3.71 Million EUR | 40.51% |
| 2016 Q1 | 684 Thousand EUR | -12.7% |
| 2015 Q4 | 783.5 Thousand EUR | 0.0% |
| 2015 Q3 | 783.5 Thousand EUR | 15.05% |
| 2015 FY | 2.64 Million EUR | 47.13% |
| 2015 Q2 | 681 Thousand EUR | 0.0% |
| 2015 Q1 | 681 Thousand EUR | 25.21% |
| 2014 Q4 | 543.86 Thousand EUR | 0.0% |
| 2014 Q1 | 353.63 Thousand EUR | 10.98% |
| 2014 Q3 | 543.86 Thousand EUR | 53.79% |
| 2014 Q2 | 353.63 Thousand EUR | 0.0% |
| 2014 FY | 1.79 Million EUR | 38.35% |
| 2013 FY | 1.29 Million EUR | -75.48% |
| 2013 Q2 | 330.07 Thousand EUR | 0.0% |
| 2013 Q3 | 318.65 Thousand EUR | -3.46% |
| 2013 Q1 | 330.07 Thousand EUR | -87.2% |
| 2013 Q4 | 318.65 Thousand EUR | 0.0% |
| 2012 Q4 | 2.57 Million EUR | 0.0% |
| 2012 FY | 5.29 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Boiron SA | 358.08 Million EUR | 99.63% |
| Laboratorios Farmaceuticos Rovi, S.A. | 483.34 Million EUR | 99.726% |
| Vetoquinol SA | 291.37 Million EUR | 99.545% |
| Valneva SE | 52.83 Million EUR | 97.49% |
| AB Science S.A. | 587 Thousand EUR | -125.894% |
| Nanobiotix S.A. | 42.35 Million EUR | 96.87% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 142.843% |
| BioSenic S.A. | 543 Thousand EUR | -144.199% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 66.122% |
| Formycon AG | 23.3 Million EUR | 94.31% |